Literature DB >> 23591126

“Meta-guidelines” for the management of patients with schizophrenia.

Stephen M Stahl1, Debbi A Morrissette2, Leslie Citrome3, Stephen R Saklad4, Michael A Cummings5, Jonathan M Meyer1, Jennifer A O'Day5, Laura J Dardashti5, Katherine D Warburton5.   

Abstract

Guidelines for treating various conditions can be helpful in setting practice standards, but the presence of several sets of guidelines from different countries, experts, and settings, written at different times, can also create confusion. Here we provide a "guideline of guidelines" for the treatment of schizophrenia, or "meta-guidelines, which not only reconcile the various existing standards but also update them to include the use of several newer agents, most of which were marketed following the publication of existing standards.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23591126     DOI: 10.1017/S109285291300014X

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  20 in total

Review 1.  Psychosis.

Authors:  David B Arciniegas
Journal:  Continuum (Minneap Minn)       Date:  2015-06

2.  Schizophrenia: overview and treatment options.

Authors:  Krishna R Patel; Jessica Cherian; Kunj Gohil; Dylan Atkinson
Journal:  P T       Date:  2014-09

3.  Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort.

Authors:  G Fond; O Godin; L Boyer; F Berna; M Andrianarisoa; N Coulon; L Brunel; E Bulzacka; B Aouizerate; D Capdevielle; I Chereau; T D'Amato; C Dubertret; J Dubreucq; C Faget; S Leignier; C Lançon; J Mallet; D Misdrahi; C Passerieux; R Rey; A Schandrin; M Urbach; P Vidailhet; P M Llorca; F Schürhoff; M Leboyer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-05-28       Impact factor: 5.270

Review 4.  Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Authors:  Matt Shirley; Caroline M Perry
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

Review 5.  A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.

Authors:  Leslie Citrome
Journal:  CNS Drugs       Date:  2013-11       Impact factor: 5.749

6.  Fatty Acid desaturase gene polymorphisms and metabolic measures in schizophrenia and bipolar patients taking antipsychotics.

Authors:  Kyle J Burghardt; Kristen N Gardner; Joshua W Johnson; Vicki L Ellingrod
Journal:  Cardiovasc Psychiatry Neurol       Date:  2013-12-21

7.  Phadiatop Seropositivity in Schizophrenia Patients and Controls: A Preliminary Study.

Authors:  Olaoluwa Okusaga; Robert G Hamilton; Adem Can; Ajirioghene Igbide; Ina Giegling; Annette M Hartmann; Bettina Konte; Marion Friedl; Gloria M Reeves; Dan Rujescu; Teodor T Postolache
Journal:  AIMS Public Health       Date:  2014-03-24

8.  Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics.

Authors:  Ludovic Samalin; Marion Garnier; Candy Auclair; Pierre-Michel Llorca
Journal:  Int J Mol Sci       Date:  2016-11-19       Impact factor: 5.923

9.  Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports.

Authors:  Yamato Kato; Ryogo Umetsu; Junko Abe; Natsumi Ueda; Yoko Nakayama; Yasutomi Kinosada; Mitsuhiro Nakamura
Journal:  J Pharm Health Care Sci       Date:  2015-04-16

10.  Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.

Authors:  Sylvain Druais; Agathe Doutriaux; Magali Cognet; Annabelle Godet; Christophe Lançon; Pierre Levy; Ludovic Samalin; Pascal Guillon
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.